



What are you looking for?

United Therapeutics Announces Promotion of Robert Roscigno to Vice President, Commercial Development

Source [Press Release](#)
Company [United Therapeutics](#)
Tags [Personnel](#)
Date [November 06, 2002](#)

Research Triangle Park, NC and Silver Spring, MD -- November 6, 2002 -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Robert Roscigno, Ph.D. has been promoted to Vice President of Commercial Development. In his new position, Dr. Roscigno is responsible for worldwide commercial development of [Remodulin ® ; \(treprostinil sodium\) Injection](#), United Therapeutics's therapy for the treatment of pulmonary arterial hypertension. Dr. Roscigno previously served as Director, Commercial Development.

"I am extremely pleased to make this promotion," said Martine Rothblatt, United Therapeutics's Chairman and CEO. "Robert was one of the principal scientific developers of [Remodulin](#) , and has also been the key individual responsible for its commercial acceptance in the United States and overseas. This promotion is emblematic of our Company's emphasis on career growth for our most talented professionals."

[Remodulin](#) received United States Food and Drug Administration approval on May 21, 2002, Canadian Therapeutic Products Directorate approval on October 4, 2002, and approval from the Israeli Ministry of Health on October 31, 2002. United Therapeutics has submitted marketing applications for [Remodulin](#) in [France](#) , [Switzerland](#) and Australia, with additional European filings to follow approval in [France](#) .

United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and [oncological](#) diseases with unique therapeutic products.

Source: Evaluate™

©2017 Evaluate Ltd. All rights reserved.



- HOME
- OUR PRODUCTS
- LATEST NEWS & INSIGHT
- SUPPORT
- CONTACT US
- SHARE THIS PAGE

- Privacy
- Terms & Conditions
- Legal
- Careers
- Sitemap
- WorkSpace Terms & Conditions

Join Us On

Twitter

2,045

HOW WE USE COOKIES

© 2017 Evaluate Ltd. ALL RIGHTS RESERVED.